119 patents
Page 5 of 6
Utility
Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
12 Oct 21
Zhiwei Wang, Yunhang Guo
Filed: 10 Jan 20
Utility
Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors
5 Oct 21
Jing Li, Haibo Zhao, Zhiwei Wang
Filed: 7 Dec 17
Utility
Pyrazolotriazolopyrimidine Derivatives As A2A Receptor Antagonist
30 Sep 21
Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same.
Guoliang ZHANG, Hanzi SUN, Changyou ZHOU
Filed: 22 Jul 19
Utility
Treatment Cancers Using a Combination Comprising BTK Inhibitors
9 Sep 21
Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent.
Nan Hu, Lai Wang, Jing Song, Tong Zhang, Kang Li, Lusong Luo, Min Wei, Zhiwei Wang, Yunhang Guo
Filed: 18 Aug 17
Utility
BCL-2 Inhibitors
2 Sep 21
Yunhang GUO, Hai XUE, Zhiwei WANG, Hanzi SUN
Filed: 29 Apr 19
Utility
Combination of a PD-1 Antagonist and a Raf Inhibitor for Treating Cancer
29 Jul 21
Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy.
Jing SONG, Lai WANG, Kang LI, Tong ZHANG, Lusong LUO, Min WEI, Zhiyu TANG, Guoliang ZHANG, Changyou ZHOU
Filed: 16 Nov 20
Utility
ANTI-PD1 Antibodies and Their Use As Therapeutics and Diagnostics
29 Jul 21
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Kang LI, Tong ZHANG, Jing SONG, Lanlan XU, Qi LIU, Hao PENG
Filed: 21 Jan 21
Utility
ANTI-OX40 Antibodies and Methods of Use
15 Jul 21
The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), a pharmaceutical composition comprising said antibody, and use of the antibody or the composition for treating a disease, such as cancer.
Ye LIU, Tong ZHANG, Zuobai WANG, Kang LI
Filed: 22 May 19
Utility
Maintenance Therapy of a Parp Inhibitor In Treating Gastric Cancer
8 Jul 21
Disclosed herein is a method for maintenance therapy of a PARP inhibitor in treating a subject with gastric cancer (GC) comprising administering to the subject a therapeutic or maintenance effective amount of a PARP inhibitor, wherein the subject had previously received chemotherapy.
Beibei JIANG, Rainer K. BRACHMANN, Yuting ZHANG, Mitch RAPONI, Heinrich FARIN, Lai WANG, Hexiang WANG
Filed: 31 May 19
Utility
Pyrazolotriazolopyrimidine Derivatives As A2A Receptor Antagonist
1 Jul 21
Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same.
Guoliang ZHANG, Changyou ZHOU
Filed: 8 Apr 19
Utility
Immunotherapy for Hepatocellular Carcinoma
20 May 21
Disclosed herein is method for the prevention, delay of progression or treatment of hepatocellular carcinoma in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of an anti-PD-1 antibody, which is an antibody or a fragment antigen binding thereof, specifically binding to human PD-1.
Lai WANG, Kang LI, Qinzhou QI, Jeannie HOU, Zhong WU
Filed: 26 Jun 18
Utility
CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF
6 May 21
The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Zhiwei WANG, Yunhang GUO, Gongyin SHI
Filed: 12 Jan 21
Utility
Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
23 Feb 21
The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Zhiwei Wang, Yunhang Guo, Gongyin Shi
Filed: 15 Aug 17
Utility
Immunomonotherapy for Urothelial Carcinoma
11 Feb 21
Disclosed herein is a method for immunotherapy of a patient with urothelial carcinoma (UC) comprising administering to the patient an anti-PD-1 antibody reduces FcγR binding thus reducing antibody-dependent phagocytosis.
James SONG, Yun ZHANG, Zhirong SHEN, Qinzhou QI
Filed: 8 Feb 19
Utility
Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof
26 Jan 21
Disclosed herein are salts of (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, and crystalline forms (polymorphs) thereof.
Hexiang Wang, Xianzhao Kuang, Changyou Zhou
Filed: 27 Feb 18
Utility
5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
4 Jan 21
Disclosed herein are 5 or 8-substituted imidazo [1, 5-a] pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo [1, 5-a] pyridines, processes for the preparation thereof and the use thereof in therapy.
Hexiang Wang, Yunhang Guo, Bo Ren, Zhiwei Wang, Guoliang Zhang, Changyou Zhou
Filed: 22 Sep 17
Utility
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
14 Dec 20
Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy.
Jing Song, Lai Wang, Kang Li, Tong Zhang, Lusong Luo, Min Wei, Zhiyu Tang, Guoliang Zhang, Changyou Zhou
Filed: 13 Jun 17
Utility
Treatment of Indolent or Aggressive B-cell Lymphomas Using a Combination Comprising BTK Inhibitors
25 Nov 20
Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-actyloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody.
James HILGER, Xiaoping ZHANG, Shibao FENG, Sunhee RO, Jane HUANG
Filed: 28 Nov 18
Utility
Anti-tigit Antibodies and Their Use As Therapeutics and Diagnostics
21 Oct 20
Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells.
Tong ZHANG, Liu XUE, Qi LIU, Min WEI, Kang LI
Filed: 28 Dec 18
Utility
Novel Benzoimidazoles As Selective Inhibitors of Indoleamine 2,3-DIOXYGENASES
7 Oct 20
Disclosed herein are novel benzoimidazoles and pharmaceutical compositions comprising at least one such novel benzoimidazoles, processes for the preparation thereof, and the method for using the same in therapy.
Hexiang WANG, Yunhang GUO, Zhiwei WANG, Changyou ZHOU
Filed: 23 Nov 18